Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 49 articles:
HTML format
Text format



Single Articles


    October 2017
  1. HAN W, Gao S, Barrett D, Ahmed M, et al
    Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  2. JING Y, Nguyen MM, Wang D, Pascal LE, et al
    DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  3. CHANG C, Liu J, He W, Qu M, et al
    A regulatory circuit HP1gamma/miR-451a/c-Myc promotes prostate cancer progression.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    August 2017
  4. GENG C, Kaochar S, Li M, Rajapakshe K, et al
    SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
    Oncogene. 2017;36:4767-4777.
    PubMed     Text format     Abstract available


    July 2017
  5. D'ABRONZO LS, Bose S, Crapuchettes ME, Beggs RE, et al
    The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  6. LI Y, Wang L, Liu J, Zhang P, et al
    O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  7. ASHIKARI D, Takayama K, Tanaka T, Suzuki Y, et al
    Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  8. CHEN WY, Tsai YC, Siu MK, Yeh HL, et al
    Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.
    Oncogene. 2017 Jul 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  9. VALENTINO A, Calarco A, Di Salle A, Finicelli M, et al
    Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.
    Oncogene. 2017 Jul 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  10. CANNISTRACI A, Federici G, Addario A, Di Pace AL, et al
    C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.
    Oncogene. 2017;36:3718-3728.
    PubMed     Text format     Abstract available


  11. TSE BWC, Volpert M, Ratther E, Stylianou N, et al
    Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.
    Oncogene. 2017;36:3417-3427.
    PubMed     Text format     Abstract available


  12. PIXBERG CF, Raba K, Muller F, Behrens B, et al
    Analysis of DNA methylation in single circulating tumor cells.
    Oncogene. 2017;36:3223-3231.
    PubMed     Text format     Abstract available


  13. PISTORE C, Giannoni E, Colangelo T, Rizzo F, et al
    DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  14. YANG J, Lu C, Wei J, Guo Y, et al
    Inhibition of KPNA4 attenuates prostate cancer metastasis.
    Oncogene. 2017;36:2868-2878.
    PubMed     Text format     Abstract available


  15. MCCURDY SR, Pacal M, Ahmad M, Bremner R, et al
    A CDK2 activity signature predicts outcome in CDK2-low cancers.
    Oncogene. 2017;36:2491-2502.
    PubMed     Text format     Abstract available


    April 2017
  16. ZONI E, Chen L, Karkampouna S, Granchi Z, et al
    CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  17. DI GIACOMO V, Tian TV, Mas A, Pecoraro M, et al
    DeltaNp63alpha promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  18. KO CJ, Lan SW, Lu YC, Cheng TS, et al
    Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  19. AI J, Pascal LE, Wei L, Zang Y, et al
    EAF2 regulates DNA repair through Ku70/Ku80 in the prostate.
    Oncogene. 2017;36:2054-2065.
    PubMed     Text format     Abstract available


    March 2017
  20. RUAN D, He J, Li CF, Lee HJ, et al
    Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  21. KIM J, Jin H, Zhao JC, Yang YA, et al
    FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  22. DART AE, Worth DC, Muir G, Chandra A, et al
    The drebrin/EB3 pathway drives invasive activity in prostate cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    December 2016
  23. SHAHRIARI K, Shen F, Worrede-Mahdi A, Liu Q, et al
    Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    November 2016
  24. BUCAY N, Sekhon K, Yang T, Majid S, et al
    MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.
    Oncogene. 2016 Nov 28. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  25. LU W, Liu S, Li B, Xie Y, et al
    SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  26. NICKERSON ML, Das S, Im KM, Turan S, et al
    TET2 binds the androgen receptor and loss is associated with prostate cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    September 2016
  27. PAUL PJ, Raghu D, Chan AL, Gulati T, et al
    Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.
    Oncogene. 2016 Sep 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  28. HULSURKAR M, Li Z, Zhang Y, Li X, et al
    Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1.
    Oncogene. 2016 Sep 19. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  29. QUEISSER A, Hagedorn S, Wang H, Schaefer T, et al
    Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    August 2016
  30. DENG X, Shao G, Zhang HT, Li C, et al
    Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Oncogene. 2016 Aug 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    July 2016
  31. CUI Y, Sun Y, Hu S, Luo J, et al
    Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  32. ZHANG Q, Liu S, Parajuli KR, Zhang W, et al
    Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  33. MARTIN PL, Yin JJ, Seng V, Casey O, et al
    Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer.
    Oncogene. 2016 Jul 4. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    June 2016
  34. SU Q, Zhang B, Zhang L, Dang T, et al
    Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer.
    Oncogene. 2016 Jun 27. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  35. CAI G, Wu D, Wang Z, Xu Z, et al
    Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization.
    Oncogene. 2016 Jun 20. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  36. CHAKRAVARTHI BV, Goswami MT, Pathi SS, Robinson AD, et al
    MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  37. OBINATA D, Takayama K, Fujiwara K, Suzuki T, et al
    Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  38. SELTH LA, Das R, Townley SL, Coutinho I, et al
    A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    May 2016
  39. ZHAO H, Lu Z, Bauzon F, Fu H, et al
    p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
    Oncogene. 2016 May 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    February 2016
  40. WILLIAMSON M, de Winter P, Masters JR
    Plexin-B1 signalling promotes androgen receptor translocation to the nucleus.
    Oncogene. 2016;35:1066-72.
    PubMed     Text format     Abstract available


  41. RICE MA, Ishteiwy RA, Magani F, Udayakumar T, et al
    The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.
    Oncogene. 2016 Feb 22. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  42. ZHENG D, Gui B, Gray KP, Tinay I, et al
    Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Oncogene. 2016 Feb 15. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  43. LEE SH, Luong R, Johnson DT, Cunha GR, et al
    Androgen signaling is a confounding factor for beta-catenin-mediated prostate tumorigenesis.
    Oncogene. 2016;35:702-14.
    PubMed     Text format     Abstract available


    January 2016
  44. PARANJAPE AN, Soundararajan R, Werden SJ, Joseph R, et al
    Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
    Oncogene. 2016 Jan 25. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    December 2015
  45. RUSCETTI M, Dadashian EL, Guo W, Quach B, et al
    HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
    Oncogene. 2015 Dec 7. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


    October 2015
  46. WARNIER M, Roudbaraki M, Derouiche S, Delcourt P, et al
    CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis.
    Oncogene. 2015;34:5383-94.
    PubMed     Text format     Abstract available


    September 2015
  47. SIU MK, Tsai YC, Chang YS, Yin JJ, et al
    Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.
    Oncogene. 2015;34:4767-76.
    PubMed     Text format     Abstract available


    August 2015
  48. MAHAJAN K, Mahajan NP
    ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.
    Oncogene. 2015;34:4162-7.
    PubMed     Text format     Abstract available


    March 2015
  49. PARISI T, Bronson RT, Lees JA
    Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancer.
    Oncogene. 2015 Mar 9. doi: 10.1038/onc.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: